Dengue vaccine study
Tuesday, 02 September, 2008
Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.
WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.
The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.
Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
